Talus Bio Analysis: $11M Raised

Identify novel drug targets in oncology and rare diseases; Develop first-in-class therapeutics targeting transcription factors; Accelerate preclinical development through toxicity prediction; Collaborate on drug discovery with innovative biotech teams; Explore gene regulation mechanisms in live cell contexts.

• Two Bear Capital
• WRF Capital
• NFX
• YC Continuity Fund
• Funders Club VC
• BoxOne Ventures

Talus Bioscience operates in the biotechnology sector, focusing on drug development for gene regulators, particularly targeting transcription factors involved in cancer. Its main competitors include:

1. Ciscovery Bio: Focuses on non-coding genomics and cis-regulatory modules (CRMs) to enhance gene therapy and drug development. Their approach may overlap with Talus's focus on gene regulatory proteins (GRPs).

2. Monte Rosa Therapeutics: Develops molecular glues to degrade disease-causing proteins, utilizing a platform that combines chemical libraries with proteomics and machine learning. This offers a different approach to targeting disease mechanisms compared to Talus.

3. Ambagon Therapeutics: Specializes in molecular glues that stabilize protein complexes, particularly in oncology, which may provide a competitive edge in cancer therapeutics.

4. KSQ Therapeutics: Uses CRISPR technology for drug discovery, focusing on tumor and immune-targeted therapies. Their CRISPRomics platform allows for genome-scale drug discovery, providing a broader approach compared to Talus's specific focus on GRPs.

5. Sapience Therapeutics: Pioneers the development of SPEARs™ to regulate transcription factors involved in cancer and immune response, offering unique therapeutic avenues that differ from Talus's methodologies.

6. Jazz Pharmaceuticals: Develops therapeutics for cancer and neurological disorders, with significant financial resources and market presence.

7. C4 Therapeutics: Focuses on developing small molecule drugs for cancer, also benefiting from substantial funding and public trading status.

8. Fog Pharmaceuticals: Specializes in developing cell-penetrating mini-proteins to target intracellular disease drivers, with considerable financial backing.

Notable differences among these competitors include their specific therapeutic focuses, technologies employed, and levels of funding, which may provide them with distinct advantages in the biotechnology landscape.

Venture capital funding and grants for drug discovery targeting undruggable diseases.

Talus Bioscience primarily focuses on the biotechnology industry, specifically in the areas of functional proteomics and cancer research, utilizing automated biology and machine learning to target transcription factor proteins involved in cancer and other diseases.

Raised $11.2M in additional funding in 2024; Collaborates with teams pushing the boundaries of biology; Focuses on previously undruggable targets in various disease areas.